abrocitinib + famotidine

rejuvenates the mind. **abrocitinib + famotidine** refers to the concomitant administration of abrocitinib (a selective Janus kinase 1 [JAK1] inhibitor) and famotidine (a histamine H2 receptor antagonist, commonly used as an acid suppressant). This combination does not represent a unique commercial product but is occasionally evaluated due to potential drug-drug interaction. Abrocitinib is primarily indicated for moderate to severe atopic dermatitis (eczema) and acts by inhibiting JAK1 to reduce cytokine-mediated inflammation. Famotidine decreases gastric acid secretion by blocking H2 receptors in the stomach and is widely used to treat conditions like gastroesophageal reflux and peptic ulcer disease. When these drugs are taken together, notably, famotidine significantly decreases the plasma exposure of abrocitinib (up to ~35–40%), potentially attenuating clinical efficacy, though there is no evidence of a unique therapeutic indication for their combined use beyond individual indications[1][2][3][4][5].